Buy the Book PDA Download

Update Me E-mail alerts The Merck Manual Minute

Print This Topic Email This Topic

Malabsorption is inadequate assimilation of dietary substances due to defects in digestion, absorption, or transport. Malabsorption can affect macronutrients (eg, proteins, carbohydrates, fats), micronutrients (eg, vitamins, minerals), or both, causing excessive fecal excretion and producing nutritional deficiencies and GI symptoms.

Pathophysiology

Digestion and absorption occur in three phases: (1) intraluminal hydrolysis of fats, proteins, and carbohydrates by enzymes—bile salts enhance the solubilization of fat in this phase; (2) digestion by brush border enzymes and uptake of end-products; and (3) lymphatic transport of nutrients. Malabsorption occurs when any of these phases is impaired.

Fats: Pancreatic enzymes split long-chain triglycerides into fatty acids and monoglycerides, which combine with bile acids and phospholipids to form micelles that pass through jejunal enterocytes. Absorbed fatty acids are resynthesized and combined with protein, cholesterol, and phospholipid to form chylomicrons, which are transported by the lymphatic system. Medium-chain triglycerides are absorbed directly.

Unabsorbed fats trap fat-soluble vitamins (A, D, E, K) and possibly some minerals, causing deficiency. Bacterial overgrowth results in deconjugation and dehydroxylation of bile salts, limiting the absorption of fats. Unabsorbed bile salts stimulate the colon, causing diarrhea.

Carbohydrates: Enzymes on microvilli lyse carbohydrates and disaccharides into constituent monosaccharides. Colonic bacteria ferment unabsorbed carbohydrates into CO₂, methane, H₂, and short-chain fatty acids (butyrate, propionate, acetate, and lactate). These fatty acids cause diarrhea. The gases cause abdominal distention and bloating.

Proteins: Enterokinase, a brush border enzyme, activates trypsinogen into trypsin, which converts many pancreatic proteases into their active forms. Active pancreatic enzymes hydrolyze proteins into oligopeptides, which are absorbed directly or hydrolyzed into amino acids.

Etiology

Malabsorption has many causes (see Table 1: Malabsorption Syndromes: Causes of Malabsorption). Some malabsorptive disorders (eg, celiac sprue) impair the absorption of most nutrients, vitamins, and trace minerals (global malabsorption); others (eg, pernicious anemia) are more selective.

Table 1
Causes of Malabsorption Mechanism Cause Inadequate gastric mixing, rapid emptying, or both Billroth II gastrectomy Gastrocolic fistula Gastroenterostomy Insufficient digestive agents Biliary obstruction Chronic liver failure Chronic pancreatitis Cholestyramine Some Trade Names QUESTRAN Click for Drug Monograph -induced bile acid loss Cystic fibrosis Lactase deficiency Pancreatic cancer Pancreatic resection Sucrase-isomaltase deficiency Improper milieu Abnormal motility secondary to diabetes, scleroderma, hyperthyroidism Bacterial overgrowth—blind loops (deconjugation of bile salts), diverticula Zollinger-Ellison syndrome (low duodenal pH) Acutely abnormal epithelium Acute intestinal infections Alcohol Neomycin Some Trade Names NEO-FRADIN NEO-RX Click for Drug Monograph Chronically abnormal epithelium Amyloidosis Celiac disease Crohn's disease Ischemia Radiation enteritis Tropical sprue Whipple's disease Short bowel Intestinal resection (eg, for Crohn's disease, volvulus, intussusception, or infarction) Jejunoileal bypass for obesity Impaired transport Abetalipoproteinemia Addison's disease Blocked lacteals— lymphoma, tuberculosis Lymphangiectasia

Pancreatic insufficiency causes malabsorption if > 90% of function is lost. Increased luminal acidity (eg, Zollinger-Ellison syndrome) inhibits lipase and fat digestion. Cirrhosis and cholestasis reduce hepatic bile synthesis or delivery of bile salts to the duodenum, causing malabsorption. Other causes are discussed elsewhere in this chapter.

Symptoms and Signs

The effects of unabsorbed substances include diarrhea, steatorrhea, abdominal bloating, and gas. Other symptoms result from nutritional deficiencies. Patients often lose weight despite adequate food intake.

Chronic diarrhea is the most common symptom and is what usually prompts evaluation of the patient. Steatorrhea—fatty stool, the hallmark of malabsorption—occurs when > 7 g/day of fat are excreted. Steatorrhea causes foul-smelling, pale, bulky, and greasy stools.

Severe vitamin and mineral deficiencies occur in advanced malabsorption; symptoms are related to the specific nutrient deficiency (see Table 2: Malabsorption Syndromes: Symptoms of Malabsorption). Vitamin B₁₂ deficiency may occur in blind loop syndrome or after extensive resection of the distal ileum or stomach.

Table 2
Symptoms of Malabsorption Symptom Malabsorbed Nutrient Anemia (hypochromic, microcytic) Iron Anemia (macrocytic) Vitamin B12, folate Bleeding, bruising, petechiae Vitamins K and C Carpopedal spasm Ca, Mg Edema Protein Glossitis Vitamins B2 and B12, folate, niacin Some Trade Names NIACOR NIASPAN SLO-NIACIN Click for Drug Monograph , iron Night blindness Vitamin A Pain in limbs, bones, pathologic fractures K, Mg, Ca, vitamin D Peripheral neuropathy Vitamins B1, B6, B12

Amenorrhea may result from malnutrition and is an important manifestation of celiac sprue in young women.

Diagnosis

• Sometimes clinically apparent diagnosis
• Blood tests to screen for consequences of malabsorption
• Stool fat testing to confirm malabsorption (if unclear)
• Cause diagnosed with endoscopy, contrast x-rays, or other tests based on findings

Malabsorption is suspected in a patient with chronic diarrhea, weight loss, and anemia. The etiology is sometimes obvious. For example, those with malabsorption due to chronic pancreatitis usually have had prior bouts of acute pancreatitis. Patients with celiac sprue can present with classic lifelong diarrhea exacerbated by gluten products and may have dermatitis herpetiformis. Those with cirrhosis and pancreatic cancer can present with jaundice. Abdominal distention, excessive flatus, and watery diarrhea occurring 30 to 90 min after carbohydrate ingestion suggest deficiency of a disaccharidase enzyme, usually lactase. Previous extensive abdominal operations suggest short bowel syndrome.

If the history suggests a specific cause, testing should be directed to that condition (see Fig. 1: Malabsorption Syndromes: Suggested evaluation for malabsorption.). If no cause is readily apparent, blood tests can be used as screening tools (eg, CBC, RBC indices, ferritin, vitamin B₁₂, folate, Ca, albumin, cholesterol, PT). These results may suggest a diagnosis and direct further investigation.

Macrocytic anemia should prompt measurement of serum folate and B₁₂ levels. Folate deficiency is common in mucosal disorders involving the proximal small bowel (eg, celiac sprue, tropical sprue, Whipple's disease). Low B₁₂ levels can occur in pernicious anemia, chronic pancreatitis, bacterial overgrowth, and terminal ileal disease. A combination of low B₁₂ and high folate levels is suggestive of bacterial overgrowth, because intestinal bacteria use vitamin B₁₂ and synthesize folate.

Microcytic anemia suggests iron deficiency, which may occur with celiac sprue. Albumin is a general indicator of nutritional state. Low albumin can result from poor intake, decreased synthesis in cirrhosis, or protein wasting. Low serum carotene (a precursor of vitamin A) suggests malabsorption if intake is adequate.

Confirming malabsorption: Tests to confirm malabsorption are appropriate when symptoms are vague and the etiology is not apparent. Most tests for malabsorption assess fat malabsorption because it is relatively easy to measure. Confirmation of carbohydrate malabsorption is not helpful once steatorrhea is documented. Tests for protein malabsorption are rarely used because fecal nitrogen is difficult to measure.

Direct measurement of fecal fat from a 72‑h stool collection is the gold standard for establishing steatorrhea but unnecessary with gross steatorrhea of obvious cause. However, this test is available routinely in only a few centers. Stool is collected for a 3‑day period during which the patient consumes ≥ 100 g fat/day. Total fat in the stool is measured. Fecal fat > 7 g/day is abnormal. Although severe fat malabsorption (fecal fat ≥ 40 g/day) suggests pancreatic insufficiency or small-bowel mucosal disease, this test cannot determine the specific cause of malabsorption. Because the test is messy, unpleasant, and time consuming, it is unacceptable to most patients and difficult to do.

Sudan III staining of a stool smear is a simple and direct, but nonquantitative, screening test for fecal fat. Acid steatocrit is a gravimetric assay done on a single stool sample; it has a reported high sensitivity and specificity (using 72‑h collection as the standard). Near-infrared reflectance analysis (NIRA) simultaneously tests stool for fat, nitrogen, and carbohydrates and may become the preferred test in the future.

Measurement of elastase and chymotrypsin in the stool can also help differentiate pancreatic and intestinal causes of malabsorption; both are decreased in pancreatic exocrine insufficiency.

The d-xylose absorption test, if available, can be done if the etiology is not obvious. It is the best noninvasive test to assess intestinal mucosal integrity and differentiate mucosal from pancreatic disease. This test has a reported specificity of 98% and sensitivity of 91% for small-bowel malabsorption.

d‑Xylose is absorbed by passive diffusion and does not require pancreatic enzymes for digestion. A normal d‑xylose test in the presence of moderate to severe steatorrhea indicates pancreatic exocrine insufficiency rather than small-bowel mucosal disease. Bacterial overgrowth syndrome can cause abnormal results because the enteric bacteria metabolize pentose, thus decreasing the d‑xylose available for absorption.

After fasting, the patient is given 25 g of d‑xylose in 200 to 300 mL of water po. Urine is collected over 5 h, and a venous sample is obtained after 1 h. Serum d‑xylose < 20 mg/dL or < 4 g in the urine sample indicates abnormal absorption. Falsely low levels can also occur in renal diseases, portal hypertension, ascites, or delayed gastric emptying time. This test is rarely used today. In addition, an abnormal D-xylose test will require an endoscopic examination with biopsies of the small-bowel mucosa. As a result, small-bowel biopsy has replaced this test to establish intestinal mucosal disease. 

Diagnosing the cause of malabsorption: More specific diagnostic tests (eg, upper endoscopy, colonoscopy, barium x-rays) are indicated to diagnose several causes of malabsorption.

Endoscopy with small-bowel biopsy is done when mucosal disease of the small bowel is suspected or if the d-xylose test is abnormal in a patient with massive steatorrhea. Aspirate from the small bowel can be sent for bacterial culture and colony count to document bacterial overgrowth. Histologic features on small-bowel biopsy (see Table 3: Malabsorption Syndromes: Small-Bowel Mucosal Histology in Certain Malabsorptive Disorders) can establish the specific mucosal disease.

Table 3
Small-Bowel Mucosal Histology in Certain Malabsorptive Disorders Disorder Histologic Characteristics Normal Fingerlike villi with a villous: crypt ratio of about 4:1; columnar epithelial cells with numerous regular microvilli (brush border); mild round cell infiltration in the lamina propria Celiac sprue (untreated) Virtual absence of villi and elongated crypts; increased intraepithelial lymphocytes and round cells (especially plasma cells) in the lamina propria; cuboidal epithelial cells with scanty, irregular microvilli Intestinal lymphangiectasia Dilation and ectasia of the intramucosal lymphatics Tropical sprue   Mild Minimal changes in villous height; moderate epithelial cell damage Severe Similar to untreated celiac disease, except that lymphocytes predominate in the lamina propria Whipple's disease Lamina propria densely infiltrated with periodic acid-Schiff-positive macrophages; villous structure may be obliterated in severe lesions

Small-bowel x-rays (eg, small-bowel follow-through, enteroclysis) can detect anatomic conditions that predispose to bacterial overgrowth. These include jejunal diverticula, fistulas, surgically created blind loops and anastomoses, ulcerations, and strictures. Abdominal flat plate x-ray may show pancreatic calcifications indicative of chronic pancreatitis. Barium contrast studies of the small bowel are neither sensitive nor specific but may have findings suggestive of mucosal disease (eg, dilated small-bowel loops, thinned or thickened mucosal folds, coarse fragmentation of the barium column).

Tests for pancreatic insufficiency (eg, secretin stimulation test, bentiromide test, pancreolauryl test, serum trypsinogen, fecal elastase, fecal chymotrypsin—see Pancreatitis: Diagnosis) are done if history is suggestive but are not sensitive for mild pancreatic disease.

The ¹⁴C-xylose breath test helps diagnose bacterial overgrowth. ¹⁴C-xylose is given orally, and the exhaled ¹⁴CO₂ concentration is measured. Catabolism of ingested xylose by the overgrowth flora causes ¹⁴CO₂ to appear in exhaled breath.

The H₂ breath test measures the exhaled H₂ produced by the bacterial degradation of carbohydrates. In patients with disaccharidase deficiencies, enteric bacteria degrade nonabsorbed carbohydrates in the colon, increasing exhaled H₂. The lactose-H₂ breath test is useful only to confirm lactase deficiency (see Malabsorption Syndromes: Diagnosis) and is not used as an initial diagnostic test in the work-up of malabsorption.

The Schilling test assesses malabsorption of vitamin B₁₂. Its 4 stages determine whether the deficiency results from pernicious anemia, pancreatic exocrine insufficiency, bacterial overgrowth, or ileal disease.

• Stage 1: The patient is given 1 μg of radiolabeled cyanocobalamin Some Trade Names
  NASCOBAL
  TWELVE RESIN-K
  Click for Drug Monograph
  po concurrent with 1000 μg of nonlabeled cobalamin IM to saturate hepatic binding sites. A 24-h urine collection is analyzed for radioactivity; urinary excretion of < 8% of the oral dose indicates malabsorption of cobalamin.
• Stage 2: If stage 1 is abnormal, the test is repeated with the addition of intrinsic factor. Pernicious anemia is present if this normalizes absorption.
• Stage 3: Stage 3 is done after adding pancreatic enzymes; normalization in this stage indicates cobalamin malabsorption secondary to pancreatic insufficiency.
• Stage 4: Stage 4 is done after antimicrobial therapy with anaerobic coverage; normalization after antibiotics suggests bacterial overgrowth.

Cobalamin deficiency secondary to ileal disease or ileal resection results in abnormalities in all stages.

Tests for less common causes of malabsorption include serum gastrin (Zollinger-Ellison syndrome), intrinsic factor and parietal cell antibodies (pernicious anemia), sweat chloride (cystic fibrosis), lipoprotein electrophoresis (abetalipoproteinemia), and plasma cortisol (Addison's disease).

Fig. 1
Suggested evaluation for malabsorption. This table is presented as a PDF and requires the free Adobe PDF reader. Get Adobe Reader

Last full review/revision January 2008 by Atenodoro R. Ruiz, Jr., MD

Content last modified January 2008